Article and Video CATEGORIES
As is fitting for Lung Cancer Awareness Month, we should become more aware of the concept of the solitary pulmonary nodule, or SPN, which is how lung cancer appears in the small proportion of (relatively) luckier people who have their lung cancer detected incidentally or in screening. Technically, it's defined as a spherically-shaped lesion that measures up to 3 cm (larger than that is considered a mass) and is entirely surrounded by lung tissue. There are two main ways that they are detected: an incidental finding on a scan done pre-operatively or for some other reason, or as part of a screening study. Specifically talking about solitary nodules (not nodules spread throughout the lungs), these aren't all cancer, and they can range from being old scar tissue to infection, inflammation, a primary lung cancer, potentially spread of another cancer to the lungs, or some other cause. As our CT scans become more and more detailed, and as CT scanners and scans are more widely available, we are seeing more and more SPNs. The more you look, the more you find.
SPNs can be managed in three basic ways. First, you can continue to watch them on repeat films over time. You can also do a biopsy, sticking a needle in and taking a sample to try to determine what it is under a microscope. Or you could just do lung surgery and take out the whole thing to find out what it is. Surgically removing a nodule is a great approach if it's cancer, but there are significant risks associated with lung surgery, and we don't want to do surgery for non-cancerous causes of lung nodules.
The features of the nodules found depend on whether we're talking about SPNs found incidentally on a scan for another cause or as part of a screening study. The ones found incidentally tend to be larger, have faster doubling times (grow faster), and are more likely to actually be cancer than ones detected in screening studies.
How common are SPNs? The studies are so different in who is included and how they're done that it's hard to make any general statements. Populations that live in areas with many lung infections (like the Southwest and Ohio River Valley) include many, many people with lots of nodules, but few that represent cancer. Populations enriched for long-term smokers are at high risk for lung nodules, and they are more likely to actually be cancer, as you'd expect. But the studies have shown that anywhere from 8% to about 50% of the scans, or people getting scans, have SPNs, so that's quite a huge range. Moreover, once a nodule is detected, we know they aren't all cancer, and the rate of these actually turning out to be malignant has been reported to be anywhere from about 1% to 12%. With that much variability in these reports, it's no wonder that the concept of screening for cancer vs. chasing down many anxiety-producing but non-cancerous nodules remains controversial.
Of course, not all lung nodules are created equal, and some look more likely to be benign while others are much more suspicious for cancer. I'll turn next to some of the factors that make us think cancer is more or less likely for a particular SPN in question.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…